Cytopia Initiates Enrollment for Second Phase II Brain Cancer Study
Posted on: Friday, 5 September 2008, 03:00 CDT
Australia-based biotechnology company Cytopia has initiated enrollment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme.
The glioblastoma multiforme (GBM) clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite of Phase II studies designed to investigate the anticancer activity of CYT997. Patient recruitment for the study will now commence, following regulatory approval in Australia and the US.
The clinical study will investigate the activity of CYT997 in combination with two other marketed anticancer agents in approximately 30 patients at a number of clinical centers in Australia and overseas. Jason Lickliter, director of oncology at the Frankston Hospital, will be the study chairman for the program.
This trial follows the successful conclusion last year of the company's Phase I safety study for intravenous CYT997, in which a prolonged delay in tumor growth was observed in seven of the study's 31 advanced cancer patients.
Cytopia is also investigating the safety and anti-vascular activity of CYT997 when administered by mouth. Preliminary data from the company's Phase I oral study indicates that the compound is well absorbed after administration in capsule form.
Enrollment for the company's Phase II study of CYT997 in relapsed multiple myeloma, a disorder of the bone marrow, is also ongoing.
Source: Datamonitor
Related Articles
- New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes
- Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
- Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
- Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in Its Phase II Clinical Study in Allergic Rhinitis Patients
- Yale-New Haven Hospital Activates Eclipsys Sunrise Clinical Manager
- Holy Spirit Health System Successfully Activates Eclipsys Sunrise Clinical Essentials in Just Ten Months
- Insmed Releases Positive Results From IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
- Cancer Patients in Western Australia to Benefit From New Treatments Using Latest Equipment From Varian Medical Systems
- AmpliMed Initiates Phase I Clinical Study of Benzimate in Patients With Advanced Refractory Cancer
- Nabi Biopharmaceuticals Announces Initiation of New StaphVAX(R) Immunogenicity Study in Orthopedic Surgery Patients
 |
 |
User Comments (0)
RSS Feeds